Corporate Governance5 Nov 2026, 08:43 pm
Symbiotec Pharmalab IPO Fund Utilization Report Filed
AI Summary
Symbiotec Pharmalab Ltd has filed its Monitoring Agency Report for the quarter ended September 30, 2026, concerning the utilization of funds raised through its Initial Public Offer (IPO). The report, issued by CARE Edge Ratings, confirms that there have been no deviations from the stated objects of the IPO. The IPO raised ₹150 crore through a fresh issue, with total issue size being ₹1,757 crore. The funds were allocated towards repayment of borrowings, general corporate purposes, and offer expenses. The monitoring agency has confirmed that the utilization aligns with the disclosures in the offer document.
Key Highlights
- No deviation in IPO fund utilization for the quarter ended Sept 30, 2026.
- Report issued by CARE Edge Ratings as per SEBI regulations.
- IPO funds utilized for debt repayment and general corporate purposes.
- Total IPO issue size was ₹1,757 crore, with ₹150 crore from fresh issue.
Price Impact
More from SYMBIOTEC